Progress in Molecular Biology and Translational Science

<p>1. Glycan-based biomarkers for diagnosis of cancers and other diseases: Past, present, and future<br>Minghui Hu, Ying Lan, Alexander Lu, Xuexiao Ma and Lijuan Zhang<br>2. Desialylation in physiological and pathological processes: New target for diagnostic and therapeutic development<br>Mohui Wei and Peng George Wang<br>3. Proteoglycans as miscommunication biomarkers for cancer diagnosis<br>Lingling Xu, Limin Tang and Lijuan Zhang<br>4. Fucosylation in cancer biology and its clinical applications<br>Ming Shan, Dandan Yang, Huaiqian Dou and Lijuan Zhang<br>5. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection<br>Yang Tang, Yidi Cui, Shufeng Zhang and Lijuan Zhang<br>6. Retrospective analysis of glycan-related biomarkers based on clinical laboratory data in two medical centers during the past six years<br>Meng Zhang, Huaiqian Dou, Dandan Yang, Ming Shan, Xiulian Li, Cui Hao, Yiran Zhang, Pengjiao Zeng, Yanli He, Yong Liu, Jing Fu, Wei Wang, Minghui Hu, Hui Li, Qingwu Tian, Shuhe Lei and Lijuan Zhang<br>7. Serum SCCA levels in patients suffering cancers or other diseases<br>Dandan Yang, Jun Wang and Lijuan Zhang<br>8. Increased serum CA724 levels in patients suffering gout vs cancers<br>Yiran Zhang, Meng Zhang, Xueshan Bai, Changgui Li and Lijuan Zhang<br>9. Serum CA50 levels in patients with cancers and other diseases<br>Ming Shan, Qingwu Tian and Lijuan Zhang<br>10. Serum AFP levels in patients suffering from 47 different types of cancers and noncancer diseases<br>Yanli He, Haijun Lu and Lijuan Zhang<br>11. Serum CEA levels in 49 different types of cancer and noncancer diseases<br>Cui Hao, Guoqing Zhang and Lijuan Zhang<br>12. CA242 as a biomarker for pancreatic cancer and other diseases<br>Huaiqian Dou, Guirong Sun, and Lijuan Zhang<br>13. Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers<br>Meng Zhang, Yiran Zhang, Jing Fu and Lijuan Zhang<br>14. Serum CA199 levels are significantly increased in patients suffering from liver, lung, and other diseases<br>Pengjiao Zeng, Hui Li, Yulong Chen, Haitao Pei and Lijuan Zhang<br>15. Serum CA153 as biomarker for cancer and non-cancer diseases<br>Xiulian Li, Yan Xu and Lijuan Zhang<br>16. Fasting blood glucose levels in patients with different types of diseases<br>Qinghua Zhang, Gang Zhao, Nailong Yang and Lijuan Zhang<br>17. HbA1c: High in acute cerebral infarction and low in brain trauma<br>Zhifeng Jiang, Jigang Wang, Peng Zhao, Lijuan Zhang and Yunliang Guo<br>18. Glycated albumin level is significantly decreased in patients suffering nephrotic syndrome<br>Zhe Wang, Guangqun Xing, Lijuan Zhang<br>19. Glycated serum proteins: High in pancreatic cancer and low in preeclampsia<br>Xueling Wang, Rui Zhang, Lijuan Zhang and Zibin Tian<br>20. The serum SA levels are significantly increased in sepsis but decreased in cirrhosis<br>Xiaodan Huang, Qin Yao, Lijuan Zhang and Zibin Tian<br>21. Serum α-L-fucosidase activities are significantly increased in patients with preeclampsia<br>Meng Zhang, Lin Wang, Haiping Zhang, Juan Cong and Lijuan Zhang<br>22. Glucuronidated bilirubin: Significantly increased in hepatic encephalopathy<br>Limin Tang, Meng Zhang, Xiulian Li and Lijuan Zhang<br>23. Serum PSA levels in patients with prostate cancer and other 33 different types of diseases<br>Yanyun Gao, Meng Zhang, Xiulian Li, Pengjiao Zeng, Peitao Wang and Lijuan Zhang</p>